Trading Away Access to Medicines (Revisited) – New report from HAI Europe and Oxfam
A new report by HAI Europe and Oxfam has found that the European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines. The lack of a widely accessible treatment for Ebola, as well as the high price of Hep-C and cancer medicines, show that it's time for the Commission to rethink its trade and innovation policies. Also see our press release.
Investor-to-state dispute settlement in EU-US trade agreement risks access to affordable medicines
HAI Europe, along with several other European and American NGOs, publicly criticised the inclusion of 'investor-to-state dispute settlement' in the Transatlantic Trade and Investment Partnership (TTIP), warning that it will undermine public health policies of European Union Member States and severely jeopardise access to affordable medicines and public health protection. To learn more, read our joint press release and response to the European Commission's public consultation on the issue.
New EMA policy on clinical trial data access a step forward, but strings attached
HAI Europe and our partners welcomed the EMA's new policy on clinical trial data access. It is a step forward in clinical trials transpancy. We are disappointed, however, that the policy gives pharmaceutical companies the ability to decide what data can be redacted on the grounds of 'commercial confidentiality'. Find out why this is bad news for both prescribers and patients in our joint statement.